KACTUS GMP-Grade Raw Materials Power World's First mRNA Shingles Vaccine into Phase III

Warm congratulations to our strategic partner, Abogen Biosciences, as they independently developed ABO1108, the world’s first mRNA shingles vaccine, officially advanced to a multi-center Phase III clinical trial stage on June 16, 2026.

ABO1108 utilizes Abogen's proprietary base-modification technology and lipid nanoparticle (LNP) delivery system, combined with a mature lyophilization formulation technology, allowing it to remain stable at 2-8°C for up to three years, which ensures excellent product stability, convenient storage, and broad accessibility.

As the first mRNA shingles vaccine in the world to enter Phase III clinical trials, this milestone not only marks a breakthrough for Abogen Biosciences in the industrialization of mRNA technology but also leaves a distinct mark of Chinese biopharmaceuticals innovation in the global landscape of shingles prevention. 

KACTUS has been deeply involved throughout the entire ABO1108 project. Backed by a fully compliant and robust GMP production and quality management system, KACTUS has provided a steady high-quality GMP-grade mRNA IVT enzymes, offering solid support for the advancement of Abogen’s pipeline. 

KACTUS GMP-grade enzymes possess three core advantages: 

• High Enzyme Activity and Superior Quality: Characterized by high purity and high activity, the GMP-grade enzymes significantly increase mRNA yield, reducing the burden on downstream purification processes.
• Stability and Batch-to-Batch Consistency: Designed to meet the needs of large-scale, multi-center clinical trials, the enzymes are produced strictly follows GMP guidelines and complies with high regulatory standards, ensuring stable and highly consistency product performance across all batches. 
• Supply Chain Resilience and Cost Optimization: Leveraging economies of scale and high manufacturing efficiency, KACTUS helps partner companies effectively control R&D costs while guaranteeing a stable supply of raw materials, thereby safeguarding the continuity of clinical trials.

Currently, KACTUS’s comprehensive quality management system has successfully passed on-site audits by dozens of global biopharmaceutical companies. Strictly adhering to relevant regulatory standards, our products ensure full compliance and data traceability for every batch of GMP-grade enzymes and other raw materials. At present, in the fields of mRNA vaccines and Cell and Gene Therapy (CGT), KACTUS's portfolio of GMP-grade raw materials has helped numerous partners successfully obtain clinical trial approvals. Multiple R&D pipelines have advanced to Phase II and III clinical trials, accelerating their journey toward commercialization.

As a key supplier of critical raw materials for biopharmaceuticals, KACTUS will continue to increase its investment. Driven by technological innovation and grounded in global compliance, we will work together with partners to build a high-quality biopharmaceutical ecosystem, and make unremitting efforts for the health and lives of more patients.